CDK4/6 inhibitors prolong OS

被引：0
|
作者：
David Killock
机构：
[1] Nature Reviews Clinical Oncology,
来源：
Nature Reviews Clinical Oncology | 2019年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：722 / 722
相关论文
共 50 条
  • [31] CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
    Yilan Yang
    Jurui Luo
    Xingxing Chen
    Zhaozhi Yang
    Xin Mei
    Jinli Ma
    Zhen Zhang
    Xiaomao Guo
    Xiaoli Yu
    Journal of Experimental & Clinical Cancer Research, 39
  • [32] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [33] Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment
    Liu, Jie
    Cheng, Min
    Xu, Jiamei
    Liang, Yue
    Yin, Beibei
    Liang, Jing
    IMMUNOLOGICAL INVESTIGATIONS, 2024, 53 (03) : 437 - 449
  • [34] CDK4/6 Inhibitors Represent Potential Psoriasis Therapeutics
    Brownell, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (11) : 2098 - 2098
  • [35] CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
    Arsenijevic, Tatjana
    Coulonval, Katia
    Raspe, Eric
    Demols, Anne
    Roger, Pierre P.
    Van Laethem, Jean-Luc
    CANCERS, 2023, 15 (03)
  • [36] CDK4/6 inhibitors in breast cancer: spotting the difference
    Jose Manuel Perez-Garcia
    Javier Cortes
    Antonio Llombart-Cussac
    Nature Medicine, 2021, 27 : 1868 - 1869
  • [37] The role of CDK4/6 inhibitors in early breast cancer
    Gil-Gil, Miguel
    Alba, Emilio
    Gavila, Joaquin
    de la Haba-Rodriguez, Juan
    Ciruelos, Eva
    Tolosa, Pablo
    Candini, Daniele
    Llombart-Cussac, Antonio
    BREAST, 2021, 58 : 160 - 169
  • [38] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [39] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [40] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
12345